Trial Profile
A Phase 1b/Adaptive Phase 2 Study of Docetaxel With or Without MLN1117 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Serabelisib (Primary) ; Docetaxel
- Indications Adenocarcinoma; Non-small cell lung cancer; Squamous cell cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Takeda Oncology
- 27 Jul 2020 This trial has been completed in United Kingdom according to European Clinical Trials Database record.
- 16 Feb 2017 Status changed from active, no longer recruiting to discontinued.
- 25 Jan 2017 This trial has been discontinued in Italy.